Chimeric antigen receptor (CAR) T cell therapy is a form of T cell engineering where T cells are obtained from a patient and engineered in a laboratory to better kill the patient's cancer cells. Specifically, CAR T cells are modified to express a receptor on their surface that recognizes the specific antigen present on the patient's cancer cells.
Though AsCas12a fills a crucial gap in the current genome editing toolbox, it exhibits relatively poor editing efficiency, restricting its overall utility. In collaboration with Integrated D...
Gene editing technologies such as CRISPR/Cas9 have greater flexibility and high efficiency. CRISPR technology enables targeted insertion of transgenes at the desired locus and has the abilit...
Date: July 8, 2021 Time: 8:00am (PDT) Cell-based chimeric antigen receptor (CAR) T cell therapies have rapidly advanced in recent years, with a variety of targets in clinical research and se...
Date: July 01, 2021 Time: 09:30am IST/12:00pm SGT/01:00pm JST, KST/03:00pm AEST/ 05:00pm NZST We know that understanding cell culture is essential for life of your work. Gibco Galaxy Tour We...
Date: June 23, 2021 Time: 9:00am PDT Adeno-associated virus (AAV) is rapidly becoming the go-to biological delivery method for the latest gene therapy breakthroughs. AAV has an efficacy and...
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy (CART19) occurs in 10% to 20% of patients with acute lymphoblastic leukemia (ALL); however, the mechanisms of thi...
Over the past 25 years, Luminex’s xMAP® Technology has emerged as the worldwide leader in bead-based multiplexing. The new xMAP® INTELLIFLEX platform combines the proven perfor...
Chimeric antigen receptor (CAR) T cells have demonstrated significant success in treating relapsed or treatment-refractory hematologic malignancies in the clinic, inducing remissions in 70-9...
Learning Objectives: 1. Define “universal CARs” and describe their mechanism of action. 2. Explain current challenges in CAR T cell therapy. 3. Describe potential benefits and ch...
Rhabdomyosarcoma (RMS) is a soft tissue cancer commonly arising in muscle and is the most common soft tissue cancer in children. Patients with metastatic RMS have a poor prognosis that has n...
DATE: May 11, 2021 TIME: 8:00am PDT T cells are most important from basic research to therapeutic approaches and play a pivotal role in many diverse application fields such as basic immu...
Engineered cell therapy is an emerging field of science to target and treat cancer. Current strategies include utilizing immune cells such as T cells, NK cells and Macrophages or other cells...
Cell therapies, including chimeric antigen receptor (CAR) T-cell therapy, are emerging as promising treatments, especially for hematological malignancies. However, many challenges remain in...
Date: April 06, 2021 Time: 8:00am (PST), 11:00am (EST) The discovery of the reproducibility crisis has called into question a worrying number of scientific results over the last few years. In...
Date: March 31, 2021 Time: 08:00am PST CytoFLEX SRT has enabled researcher lead self-service sorting. The need for a cell sorting expert to setup and maintain the sorter status is now necess...
DATE: March 30, 2021 TIME: 08:00am PST In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effect...
Date: February 10, 2021 Time: 8:00am (PST), 11:00am (EST) Uncovering the interactions between the immune system and cancer cells or pathogens is key for understanding and controlling both ca...
Date: February 3, 2021 Time: 8:00am (PST), 11:00am (EST) This introduction webinar will provide you with an overview of the general immuno-oncology (IO) research field...
Date: November 17, 2020 Time: 8:00am COVID-19 is a complex pathological condition caused by infection with SARS-CoV. Different features have been observed in patients with a severe dis...
DATE: November 5, 2020 TIME: 9:00am (PDT), 12:00pm (EDT) With accelerating development and approval of cell therapies, biologic drugs, and antiviral treatments comes a need for more robust a...
DATE: November 4th, 2020 TIME: 11:00am PST As cell therapies become more complex, the need for robust analytical tools to characterize such products as they enter the clinic has increased in...
On measuring photons and ions: Impact on panel design, signal detection and data quality 10:30–11:00 am PDT Presented By: Tim Bushnell, PhD, MBA Monitoring immunotherapy with a mass cy...
Single-cell mass cytometry identifies mechanisms of resistance to immunotherapy in AML 6:30–7:00 am PDT Presented By: Shelley Herbrich, PhD Understanding CD19 negative relapse followin...
Though AsCas12a fills a crucial gap in the current genome editing toolbox, it exhibits relatively poor editing efficiency, restricting its overall utility. In collaboration with Integrated D...
Gene editing technologies such as CRISPR/Cas9 have greater flexibility and high efficiency. CRISPR technology enables targeted insertion of transgenes at the desired locus and has the abilit...
Date: July 8, 2021 Time: 8:00am (PDT) Cell-based chimeric antigen receptor (CAR) T cell therapies have rapidly advanced in recent years, with a variety of targets in clinical research and se...
Date: July 01, 2021 Time: 09:30am IST/12:00pm SGT/01:00pm JST, KST/03:00pm AEST/ 05:00pm NZST We know that understanding cell culture is essential for life of your work. Gibco Galaxy Tour We...
Date: June 23, 2021 Time: 9:00am PDT Adeno-associated virus (AAV) is rapidly becoming the go-to biological delivery method for the latest gene therapy breakthroughs. AAV has an efficacy and...
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy (CART19) occurs in 10% to 20% of patients with acute lymphoblastic leukemia (ALL); however, the mechanisms of thi...
Over the past 25 years, Luminex’s xMAP® Technology has emerged as the worldwide leader in bead-based multiplexing. The new xMAP® INTELLIFLEX platform combines the proven perfor...
Chimeric antigen receptor (CAR) T cells have demonstrated significant success in treating relapsed or treatment-refractory hematologic malignancies in the clinic, inducing remissions in 70-9...
Learning Objectives: 1. Define “universal CARs” and describe their mechanism of action. 2. Explain current challenges in CAR T cell therapy. 3. Describe potential benefits and ch...
Rhabdomyosarcoma (RMS) is a soft tissue cancer commonly arising in muscle and is the most common soft tissue cancer in children. Patients with metastatic RMS have a poor prognosis that has n...
DATE: May 11, 2021 TIME: 8:00am PDT T cells are most important from basic research to therapeutic approaches and play a pivotal role in many diverse application fields such as basic immu...
Engineered cell therapy is an emerging field of science to target and treat cancer. Current strategies include utilizing immune cells such as T cells, NK cells and Macrophages or other cells...
Cell therapies, including chimeric antigen receptor (CAR) T-cell therapy, are emerging as promising treatments, especially for hematological malignancies. However, many challenges remain in...
Date: April 06, 2021 Time: 8:00am (PST), 11:00am (EST) The discovery of the reproducibility crisis has called into question a worrying number of scientific results over the last few years. In...
Date: March 31, 2021 Time: 08:00am PST CytoFLEX SRT has enabled researcher lead self-service sorting. The need for a cell sorting expert to setup and maintain the sorter status is now necess...
DATE: March 30, 2021 TIME: 08:00am PST In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effect...
Date: February 10, 2021 Time: 8:00am (PST), 11:00am (EST) Uncovering the interactions between the immune system and cancer cells or pathogens is key for understanding and controlling both ca...
Date: February 3, 2021 Time: 8:00am (PST), 11:00am (EST) This introduction webinar will provide you with an overview of the general immuno-oncology (IO) research field...
Date: November 17, 2020 Time: 8:00am COVID-19 is a complex pathological condition caused by infection with SARS-CoV. Different features have been observed in patients with a severe dis...
DATE: November 5, 2020 TIME: 9:00am (PDT), 12:00pm (EDT) With accelerating development and approval of cell therapies, biologic drugs, and antiviral treatments comes a need for more robust a...
DATE: November 4th, 2020 TIME: 11:00am PST As cell therapies become more complex, the need for robust analytical tools to characterize such products as they enter the clinic has increased in...
On measuring photons and ions: Impact on panel design, signal detection and data quality 10:30–11:00 am PDT Presented By: Tim Bushnell, PhD, MBA Monitoring immunotherapy with a mass cy...
Single-cell mass cytometry identifies mechanisms of resistance to immunotherapy in AML 6:30–7:00 am PDT Presented By: Shelley Herbrich, PhD Understanding CD19 negative relapse followin...
Opens in a new windowOpens an external siteOpens an external site in a new window
Follow
